Valuation Result

Final Brand Value

Coloplast — Healthcare Products

Valuation date: 10/30/2026

Total Brand Value

DKK 5.9B

This result turns the selected legal, brand, benchmark and discount-rate assumptions into one reviewable brand value estimate.

Brand Strength

80/100

Royalty Rate

1.6%

Discount Rate

8.5%

Benchmark recommendation not unlocked for this result

Sensitivity snapshot

Quick decision check for discount rate, royalty rate and long-term growth.

Variable

Lower input

Current

Higher input

WACC (Discount Rate)

8.5%

-1.0%

DKK 6.9B

8.5%

DKK 5.9B

+1.0%

DKK 5.1B

Royalty Rate

1.6%

-0.5%

DKK 4.0B

1.6%

DKK 5.9B

+0.5%

DKK 7.7B

Terminal Growth

2.0%

-0.5%

DKK 5.5B

2.0%

DKK 5.9B

+0.5%

DKK 6.3B

Brand Strength changes can also be explored to show their potential effect on brand value. Contact info@brandvaluator.se if you want to explore this for strategy, planning and budgeting.

Revenue Base

DKK 24.3B

Legal Protection

82/100

Long-term Growth

2.0%

Recommendation basis

Brand-strength range • Pro

This reference case derives its royalty rate by applying the brand-strength score to a documented industry royalty ceiling.

This valuation uses benchmark support informed by external market references and curated internal calibration.

Use this section to confirm whether the result reflects unlocked benchmark guidance or a non-benchmark method.

Forecast profile

5 years explicit forecast

High growth: 7.0%

Base growth: 4.0%

Long-term growth: 2.0%

Value build

Value for planning period: DKK 1.5B

Terminal value: DKK 4.4B

How the valuation is built

Valuation Build

Royalty Relief DCF

Year	Revenue	Royalty	After Tax	PV
Y1	DKK 26,043,800,000	DKK 416,700,800	DKK 325,026,624	DKK 312,035,544
Y2	DKK 27,866,866,000	DKK 445,869,856	DKK 347,778,488	DKK 307,721,689
Y3	DKK 29,817,546,620	DKK 477,080,746	DKK 372,122,982	DKK 303,467,472
Y4	DKK 31,010,248,485	DKK 496,163,976	DKK 387,007,901	DKK 290,881,263
Y5	DKK 32,250,658,424	DKK 516,010,535	DKK 402,488,217	DKK 278,817,064
Explicit PV (Y1–Y5)				DKK 1,492,923,032
Terminal Value (undiscounted)				DKK 6,315,968,946
Terminal PV (discounted)				DKK 4,375,283,152
Total Brand Value				DKK 5,868,206,184

Supporting context

This section explains the evidence and judgment used to support the recommendation and the legal, brand and financial assumptions used in the valuation.

Reference case

Coloplast

Prepared reference case

Indicative value of the Coloplast name in ostomy, continence, urology and wound care. Atos Medical, TRACOE, Kerecis, product patents, reimbursement listings and enterprise value are excluded.

Segment operating profit is reported before shared costs and special items; matched EBIT for the selected segments is not published. The capacity check therefore uses group EBIT, which includes the excluded segments. FY2025/26 guidance is about 7% organic growth. The 2.00% name-only ceiling and 1.600% selected royalty are analyst assumptions, not an observed licence. Opening hypothetical rent of DKK 389.4m is about 5.4% of DKK 7.201bn FY2024/25 group EBIT; this is not a matched name-profit test. Legal and behavioural inputs are outside-in estimates, not a trademark opinion or customer survey.

Informed by numerous sources including company reporting, investor materials, analyst research, market data and selected benchmark references where relevant.

Key inputs

Reported = directly sourced • Estimated = selected judgment • Inferred = derived from broader evidence • Assumed = inclusion choice

Revenue base

DKK 24.340bn FY2024/25 Coloplast-branded segment revenueinferred

Planning growth

7.00% for 3 years, then 4.00%estimated

Long-term growth

2.00%estimated

Royalty rate selected

1.60%estimated

Discount rate

8.50%estimated

Brand Strength

80/100 (A-)estimated

Legal analysis

82/100estimated

Company disclosures

These links lead to company-issued materials. BrandValuator cross-checks indicative estimates against multiple sources; the final assumptions and judgments are our own. Each input is labeled by evidence status above.

Coloplast Annual Report 2024/25, Note 4 Segment information (segment revenue and segment operating profit); At a glance p.3

Legal Protection

trademark Status90

scope Of Rights86

risk Profile76

litigation76

contractual Rights80

goodwill Evidence86

regulatory Compliance80

Brand Strength

marketing Investment72

quality88

availability84

distinctive Brand Codes80

mental Availability80

consideration82

trust86

choice Share82

penetration80

price Elasticity66

revenue Premium72

margin Premium78

stability84